ARWR · XBRL financial data

Arrowhead Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ARWR's year ends in late September)

In millions of dollars	Q4 FY23Sep 30, 2023	Q1 FY24Dec 31, 2023	Q2 FY24Mar 31, 2024	Q3 FY24Jun 30, 2024	Q4 FY24Sep 30, 2024	Q1 FY25Dec 31, 2024	Q2 FY25Mar 31, 2025	Q3 FY25Jun 30, 2025	Q4 FY25Sep 30, 2025	Q1 FY26Dec 31, 2025	Q2 FY26Mar 31, 2026	Q3 FY26Jun 30, 2026
Revenue from contracts with customers	16*	4	0	0	0*	3	543	28	256*	264	74	75
Research and development	year only	—	—	—	year only	137	133	162	175*	177	173	198
Selling, general and administrative	—	—	—	—	—	—	28	31	—	—	42	47
General and administrative	25*	24	25	24	26*	27	28	31	38*	46	—	—
Total operating expenses	124*	140	126	176	162*	164	162	193	212*	223	215	245
Operating income (loss)	(108)*	(137)	(126)	(176)	(162)*	(161)	381	(166)	44*	41	(141)	(170)
Interest expense	5*	5	7	5	15*	22	22	24	22*	23	24	25
Other income (expense)	1*	0	0	1	(3)*	0	0	(0)	5*	0	(2)	1
Income tax expense (benefit)	2*	(3)	0	0	1*	0	2	(0)	20*	0	0	0
Net income (loss)	(110)*	(133)	(125)	(171)	(171)*	(173)	370	(175)	(24)*	31	(133)	(194)
Earnings per share, basic USD per share	(1.02)*	(1.24)	(1.02)	(1.38)	(1.37)*	(1.39)	2.78	(1.26)	(0.17)*	0.22	(0.93)	(1.36)
Earnings per share, diluted USD per share	(1.04)*	(1.24)	(1.02)	(1.38)	(1.37)*	(1.39)	2.75	(1.26)	—	0.22	(0.93)	(1.36)
Weighted average shares, basic millions of shares	107*	107	123	124	124*	125	133	139	138*	137	142	143
Weighted average shares, diluted millions of shares	106*	107	123	124	124*	125	134	139	137*	141	142	143

Fiscal quarters (ARWR's year ends in late September)

In millions of dollars	Q4 FY23Sep 30, 2023	Q1 FY24Dec 31, 2023	Q2 FY24Mar 31, 2024	Q3 FY24Jun 30, 2024	Q4 FY24Sep 30, 2024	Q1 FY25Dec 31, 2024	Q2 FY25Mar 31, 2025	Q3 FY25Jun 30, 2025	Q4 FY25Sep 30, 2025	Q1 FY26Dec 31, 2025	Q2 FY26Mar 31, 2026	Q3 FY26Jun 30, 2026
Cash and cash equivalents	111	58	128	69	103	54	186	130	227	202	189	55
Short-term investments	—	—	—	—	—	—	—	—	693	715	1,596	—
Marketable securities	293	162	395	367	578	499	912	771	693	714	1,595	1,547
Accounts receivable	0	—	—	—	0	3	2	10	7	219	16	9
Total current assets	420	238	542	450	695	571	1,135	947	951	1,174	1,840	1,671
Property and equipment, net	290	333	359	376	386	387	385	381	383	379	375	373
Right-of-use asset	45	45	45	44	45	45	44	44	44	43	43	56
Total assets	766	626	955	884	1,140	1,014	1,573	1,381	1,385	1,604	2,268	2,112
Accounts payable	36	4	9	27	11	14	10	33	18	33	31	28
Accrued liabilities	40	47	37	48	63	59	78	65	90	130	77	86
Total current liabilities	105	64	65	97	103	94	221	195	195	347	295	283
Lease liability, non-current	105	115	114	112	111	109	108	106	104	102	100	114
Accumulated deficit	(1,026)	(1,159)	(1,284)	(1,455)	(1,626)	(1,799)	(1,428)	(1,603)	(1,627)	(1,596)	(1,729)	(1,923)
Total stockholders' equity	271	160	484	331	185	53	683	522	466	568	614	466
Total liabilities and equity	766	626	955	884	1,140	1,014	1,573	1,381	1,385	1,604	2,268	2,112
Common shares outstanding (cover page) millions of shares	107	124	124	124	124	126	138	138	136	140	141	141

Fiscal quarters (ARWR's year ends in late September)

In millions of dollars	Q4 FY23Sep 30, 2023	Q1 FY24Dec 31, 2023	Q2 FY24Mar 31, 2024	Q3 FY24Jun 30, 2024	Q4 FY24Sep 30, 2024	Q1 FY25Dec 31, 2024	Q2 FY25Mar 31, 2025	Q3 FY25Jun 30, 2025	Q4 FY25Sep 30, 2025	Q1 FY26Dec 31, 2025	Q2 FY26Mar 31, 2026	Q3 FY26Jun 30, 2026
Net income (loss)	(110)*	(133)	(125)	(171)	(171)*	(173)	370	(175)	(24)*	31	(133)	(194)
Stock-based compensation	18*	20	18*	17*	19*	15	16*	13*	19*	19	17*	15*
Depreciation and amortization	3*	4	4	4	5*	5	6	6	6*	6	6	6
Net cash from operating activities	(25)*	(118)	(92)*	(115)*	(137)*	(146)	460*	(155)*	20*	13	84*	(177)*
Purchases of property and equipment	64*	69	34*	14*	24*	8	5*	2*	7*	2	3*	4*
Net cash from investing activities	31*	65	(269)*	7*	(223)*	77	(420)*	141*	73*	(24)	(894)*	44*
Proceeds from issuing common stock	0*	—	—	0*	0*	0	241*	0*	0*	47	—	—
Net cash from financing activities	0*	0	431*	50*	389*	21	92*	(43)*	4*	(15)	796*	(0)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Arrowhead Pharmaceuticals	55	75	(177)*	141.3M	9.0 quarters	Q3 FY26 10-QJun 30, 2026
Adaptive Biotechnologies	170	72	(6.4)*	159.6M	53.8 quarters	Q2 FY26 10-QJun 30, 2026
Avadel Pharmaceuticals	80	77	22*	97.7M	—	Q3 FY25 10-QSep 30, 2025
Travere Therapeutics	124	225	98*	96.0M	—	Q3 FY26 10-QSep 30, 2026
Ani Pharmaceuticals	360	266	57*	not reported	—	Q2 FY26 10-QJun 30, 2026
Celldex Therapeutics	47	0	(57)*	78.5M	12.5 quarters	Q2 FY26 10-QJun 30, 2026
Innoviva	570	120	52*	72.2M	—	Q2 FY26 10-QJun 30, 2026
Ligand Pharmaceuticals	56	79	(28)*	20.0M	—	Q3 FY26 10-QSep 30, 2026
Ocular Therapeutix	599	13	(67)*	219.6M	8.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.